Bosma arhinia microphthalmia syndrome

Bosma arhinia microphthalmia syndrome
Other names
  • Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome
  • Bosma syndrome
SpecialtyMedical genetics
Symptoms
CausesMutations in SMCHD1 gene

Bosma arhinia microphthalmia syndrome (BAMS) is a rare genetic disorder characterized by nasal and ocular abnormalities, often accompanied by endocrine dysfunction.

Presentation

The typical indicator of BAMS is arrhinia, characterized by the complete absence of an external nose or, in some cases, a severely underdeveloped (hypoplastic) nose.[1][2] This is often accompanied by the absence of olfactory bulb, leading to impaired smell (hyposmia or anosmia) and taste (ageusia).[1] Patients typically exhibit microphthalmia (abnormally small eyeballs) or anophthalmia (absence of eyeballs), resulting in severe vision impairment or blindness.[2][3] Additional eye abnormalities may include colobomas, cataracts, and nasolacrimal duct obstruction.[1] Common craniofacial abnormalities include a high-arched or cleft palate, absence of paranasal sinuses, choanal atresia, and a hypoplastic maxilla. Some patients may also present with external ear abnormalities.[1][2] BAMS is associated with hypogonadotropic hypogonadism, leading to absent or delayed puberty and sexual development. This can manifest as underdeveloped genitals in males and lack of breast development or menstruation in females.[1] Despite the severe craniofacial abnormalities, patients with BAMS typically have normal cognition and intellectual abilities.[1]

Genetics

Bosma arhinia microphthalmia syndrome is primarily caused by de novo mutations in the N-terminal GHKL-type ATPase domain of the SMCHD1 gene, which encodes a protein that regulates chromatin structure and gene silencing during embryogenesis and is important for craniofacial development.[4][2][5] The mutations are thought to produce a gain-of-function effect that disrupts normal nasal and ocular development.[6][7] BAMS follows an autosomal dominant inheritance pattern, so a single mutated copy of SMCHD1 can cause the disorder.[2][5]

Diagnosis

The condition is typically diagnosed at birth from physical examination findings such as the absence of the nose and small or absent eyes.[5][2] However, genetic testing is needed to confirm the diagnosis by using techniques such as next-generation sequencing to identify mutations in the SMCHD1 gene. Genetic testing is required to distinguish BAMS from other syndromes that present with similar craniofacial abnormalities, such as CHARGE syndrome or Treacher Collins syndrome.[3][1][8]

Treatment

Treatment is symptomatic and individualised, and usually requires a team of pediatricians, endocrinologists, ophthalmologists, and craniofacial surgeons. Nasal reconstruction and ocular prosthesis have been used to improve breathing and the cosmetic appearance of the face.[3][9][10]

Individuals with BAMS commonly experience hypogonadotropic hypogonadism due to disrupted gonadotropin-releasing hormone (GnRH) neurons. Hormone therapy can help manage this condition by supplementing deficient hormones.[4][8] Genetic counseling and psychological support are often recommended for patients and their families.[5][10]

References

  1. 1 2 3 4 5 6 7 Cong, N. V.; Minh, L. H.; Hoang, L. H.; Do, U.; Dung, N. T. (20 February 2023). "Bosma Arhinia Microphthalmia Syndrome (BAMS): First Report from Vietnam". Cureus. 15 (2) e35222. doi:10.7759/cureus.35222. PMC 10032420. PMID 36968924.
  2. 1 2 3 4 5 6 "Bosma arhinia microphthalmia syndrome" (PDF). MedlinePlus. Retrieved 17 December 2024.
  3. 1 2 3 "Ocular Manifestations of Bosma Arrhinia Microphthalmia Syndrome (BAMS) - EyeWiki". eyewiki.org. Retrieved 2024-12-17.
  4. 1 2 Atencia Goñi, José; Orera Clemente, María; Del Valle Diéguez, Mariano José; González Fernández, Laura; González Albarrán, Olga (2024-03-01). "Clinical report of Bosma arhinia microphthalmia syndrome with a new variant on SMCHD1 gene. A case report". Endocrinología, Diabetes y Nutrición (in Spanish). 71 (3): 138–143. doi:10.1016/j.endinu.2023.12.011. ISSN 2530-0164. PMID 38555111.
  5. 1 2 3 4 A, Syed S. (2024-09-27). "What is Bosma Arhinia Microphthalmia Syndrome?". News-Medical. Retrieved 2024-12-17.
  6. ↑ Gurzau, A. D.; Chen, K.; Xue, S.; Dai, W.; Lucet, I. S.; Ly, T. T.; Reversade, B.; Blewitt, M. E.; Murphy, J. M. (10 May 2018). "FSHD2- and BAMS-associated mutations confer opposing effects on SMCHD1 function". The Journal of Biological Chemistry. 293 (25): 9841–9853. doi:10.1074/jbc.RA118.003104. PMC 6016475. PMID 29748383.
  7. ↑ Lemmers, R. J.; Van Der Stoep, N.; Van Der Vliet, P. J.; Moore, S. A.; Granado, D. S.; Johnson, K.; Topf, A.; Straub, V.; Evangelista, T.; Mozaffar, T.; Kimonis, V.; Selvatici, R.; Ferlini, A.; Voermans, N.; Van Engelen, B.; Sacconi, S.; Tawil, R.; Lamers, M.; Van Der Maarel, S. M. (26 June 2019). "SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain". Journal of Medical Genetics. 56 (10): 693–700. doi:10.1136/jmedgenet-2019-106168. PMC 6800092. PMID 31243061.
  8. 1 2 Brasseur, Benjamin; Martin, Cindy M.; Cayci, Zuzan; Burmeister, Lynn; Schimmenti, Lisa A. (May 2016). "Bosma arhinia microphthalmia syndrome: Clinical report and review of the literature". American Journal of Medical Genetics. Part A. 170A (5): 1302–1307. doi:10.1002/ajmg.a.37572. ISSN 1552-4833. PMID 26842768.
  9. ↑ Brusati, Roberto; Colletti, Giacomo (May 2012). "The Role of Maxillary Osteotomy in the Treatment of Arhinia". Journal of Oral and Maxillofacial Surgery. 70 (5): e361–e368. doi:10.1016/j.joms.2012.01.009. hdl:11380/1252008. PMID 22364860.
  10. 1 2 "Bosma Arhinia Microphthalmia Syndrome - Symptoms, Causes, Treatment | NORD". rarediseases.org. Retrieved 2024-12-17.